Q3 Earnings Estimate for Medtronic Issued By Leerink Partnrs

Key Points

• Analysts at Leerink Partners have reduced their Q3 2026 earnings per share estimate for Medtronic from $1.37 to $1.36, while the consensus for the current full year stands at $5.46 EPS.
• Medtronic recently announced a quarterly dividend of $0.71 per share, reflecting a 2.9% dividend yield, with the next payment set for October 17th.
• Institutional investors control approximately 82.06% of Medtronic's stock, indicating strong institutional interest in the company.

Medtronic PLC (NYSE:MDT - Free Report) - Analysts at Leerink Partnrs decreased their Q3 2026 earnings per share estimates for shares of Medtronic in a research report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now anticipates that the medical technology company will post earnings per share of $1.36 for the quarter, down from their previous forecast of $1.37. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic's FY2028 earnings at $6.66 EPS, FY2029 earnings at $7.15 EPS and FY2030 earnings at $7.67 EPS.

Other equities analysts have also issued reports about the company. Wolfe Research upgraded Medtronic from an "underperform" rating to a "peer perform" rating in a research note on Monday, June 30th. Truist Financial lifted their price objective on Medtronic from $92.00 to $96.00 and gave the stock a "hold" rating in a research note on Thursday, August 21st. Wells Fargo & Company lifted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 20th. Needham & Company LLC reiterated a "hold" rating on shares of Medtronic in a research note on Thursday, August 14th. Finally, BTIG Research reissued a "neutral" rating on shares of Medtronic in a research report on Friday, July 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $102.41.

Medtronic Price Performance

NYSE MDT opened at $96.56 on Wednesday. Medtronic has a fifty-two week low of $79.29 and a fifty-two week high of $99.37. The stock's 50-day moving average is $93.82 and its two-hundred day moving average is $88.85. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The firm has a market cap of $123.86 billion, a P/E ratio of 26.60, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company's revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS.

Hedge Funds Weigh In On Medtronic

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 1248 Management LLC acquired a new position in shares of Medtronic during the 1st quarter worth about $26,000. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic during the 2nd quarter worth about $27,000. Columbia River Financial Group LLC acquired a new position in shares of Medtronic during the 1st quarter worth about $28,000. Twin Tree Management LP acquired a new position in shares of Medtronic during the 1st quarter worth about $29,000. Finally, Activest Wealth Management boosted its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock worth $30,000 after buying an additional 322 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the company's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares of the company's stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic's payout ratio is 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.